Search
Zhongsheng Pharmaceutical: Marketing Approval Secured for Alclofenac Bulk Drug from Wholly-Owned Subsidiary
1 week ago /
Read about 0 minute
Author：小编
Zhongsheng Pharmaceutical's wholly-owned subsidiary, Guangdong Xianqiang Pharmaceutical Co., Ltd., has recently secured approval from the National Medical Products Administration for the marketing of Alclofenac bulk drug. Alclofenac, a potent blood lipid regulator, works by lowering very low-density lipoprotein (VLDL) levels and is integral to various pharmaceutical formulations. This milestone reinforcement not only bolsters Xianqiang Pharmaceutical's bulk drug portfolio but also paves the way for further research and development initiatives, as well as market expansion opportunities.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
